Work

Supplementary Figures 1-8 from Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency

Year: 2023
Type: supplementary-materials
Abstract: Figure S1A. Binding affinities of OMP-59R5 to human (h) Notch1-4 receptors; Figure S1B. Alignment of the EGF repeats 10-15 of Notch2 and 9-14 of Notch3 from human (h), cynomolgus monkey (cyno), and mouse (m); Figure S2. Human NOTCH1, NOTCH2 and NOTCH3 gene in patient-derived primary xenograft tumors; Figure S3. Effect of OMP-59R5 on tumor growth of individual animals in OMP-PN8 and OMP-PN17 xenografts (from Figure 2); Figure S4A. Effect of OMP-59R5 on goblet cells; Figure S4B. Effect of OMP-59R5 on teeth in NOD/SCID mice; Figure S5. Effect of OMP-59R5 on (a) gene expression, (b) Human vimentin IHC (c) Western blot of Notch3 transmembrane domain (TM) and Notch3 intracellular domain (ICD) protein levels and (d) Quantitation of Notch1 ICD staining intensity levels in pancreatic xenograft tumors; Figure S6A. Effect of OMP-59R5 in combination with gemcitabine or gemcitabine/nab-paclitaxel in OMP-PN8 xenograft tumors; Figure S6B. Effect of OMP-59R5 in combination with gemcitabine/nab-paclitaxel on body weight change in OMP-PN8 xenograft tumor-bearing NOD/SCID mice (from Figure 4B); Figure S6C. Activity of OMP-59R5 in combination with nab-paclitaxel plus gemcitabine in OMP-PN16; Figure S8A. Perfused vessels are associated with the presence of desmin; Figure S8B. Quantification of perfused blood vessels; Figure S8C. Targeting DLL4/Notch signaling and Notch2/3 signaling has opposite effect on tumor stroma/vasculature; Figure S7A. Anti-tumor effect of OMP-59R5 in SCLC tumors; Figure S7B. Effect of OMP-59R5 on Notch3 ECD and Notch3 ICD expression in UM-PE13 xenograft tumors; Figure S7C. Limiting Dilution Assay
Language: English
Open Access status: gold
OpenAlex ID: W4362432857
Cites:
Cited by:
Related to: 10